Protective Role Of The Depressor Arm Of The Renin-angiotensin System During Pregnancy
Funder
National Health and Medical Research Council
Funding Amount
$633,384.00
Summary
The motivation for unveiling the normal hormonal and molecular mechanisms involved in the extraordinary vasodilatation associated with pregnancy is that understanding these fundamental processes may provide novel insights into the pathophysiology of preeclampsia and intrauterine growth restriction, as well as potential therapeutic strategies for not only the treatment of these pregnancy specific conditions but also cardiovascular and renal diseases in non-pregnant women and men.
Associate Professor Kate Denton is an internationally recognised cardiovascular researcher. A focus of Dr Denton’s research is to find out why women do not respond to current treatments as well as men, and how factors in pregnancy (nutrition, stress, alcohol) drive the development of cardiovascular disease in offspring. Dr Denton is also leading research to understand why a new high blood pressure treatment (blocking nerves to the kidney) is proving more effective than expected.
Mechanism Of Epidermal Growth Factor Receptor Transactivation
Funder
National Health and Medical Research Council
Funding Amount
$578,268.00
Summary
This application examines the cellular events that control heart growth in response to angiotensin, a hormone linked to heart failure. We believe that the same cell processes are also involved in cancer cell growth and by understanding the mechanism by which angiotensin promotes growth, better therapies against human cardiovascular disease and its relationship to uncontrolled growth will evolve.
Interactions Between RAGE And The Type 1 Angiotensin Receptor Determine The Pro-atherosclerotic Actions Of Angiotensin II
Funder
National Health and Medical Research Council
Funding Amount
$521,956.00
Summary
Heart attacks and strokes are a major cause of death and disability in Australians. Activation of the renin angiotensin system plays a key role in the development and progression of atherosclerosis, the process that leads to narrowing and obstruction of arteries. In preliminary data we have found a way to block these pathways without affecting the control of blood pressure. We believe that interventions based on these data will be important for the prevention and treatment of heart disease.
In Vivo Studies On Ventriculo-vascular Coupling And The Role Of Aortic Pressure Wave Morphology On Coronary Blood Flow
Funder
National Health and Medical Research Council
Funding Amount
$137,700.00
Summary
Heart disease is a leading cause of death and disability in Australia. Conditions resulting in reduced blood flow to the heart are particularly common and dangerous. Despite significant progress, we still do not understand exactly how changes in heart function and the aorta (the major artery arising from the heart) affect blood flow to the heart. This study will utilise sophisticated new techniques to look at the interactions between heart function, pressure in the aorta and coronary blood flow
Unique Isoform-specific Regulation Of Cardiac Ryanodine Receptors By Calcium Store Proteins
Funder
National Health and Medical Research Council
Funding Amount
$421,160.00
Summary
The importance of proteins that regulate calcium stores of heart muscle is graphically illustrated by massive changes in cell structure and function, which lead to ventricular fibrillation and fatality when the proteins are disrupted. We recently made the remarkable discovery that the proteins have a unique action in the heart which enhances cardiac contraction. We will discover the interaction sites between the proteins and will define novel therapeutic targets for heart failure.
DEFINING NONCLASSICAL ANGIOTENSIN SIGNALLING AND CARDIOVASCULAR FUNCTION
Funder
National Health and Medical Research Council
Funding Amount
$634,580.00
Summary
Angiotensin II is a hormone which is well known to contribute to high blood pressure and cardiovascular disease. This proposal will use highly novel compounds that we have synthesised that, for the first time, selectively target nonclassical angiotensin-related binding sites, so called NON-AT1 receptors, which are thought to counteract the deleterious effects of angiotensin II that normally causes fibrosis or scarring of the heart which damages healthy muscle.
UTILITY OF NOVEL BIOMARKERS IN THE PREDICTION OF MAJOR COMPLICATIONS OF TYPE II DIABETES MELLITUS
Funder
National Health and Medical Research Council
Funding Amount
$510,639.00
Summary
Diabetes is increasingly common. It can cause a variety of complications, the most serious being heart and kidney disease. The reasons why some patients develop such complications are not fully understood so it is difficult to predict who will be affected. The current project will use samples from a large international study of patients with diabetes to assess whether levels of specific markers in the blood help to predict major complications and clarify why they occur.
Elucidation Of The Genetic Mechanisms Of Primary Aldosteronism: The Most Common, Curable Form Of Hypertension
Funder
National Health and Medical Research Council
Funding Amount
$334,338.00
Summary
Hypertension is a major cardiovascular risk factor that affects 10-40% of the population. The steroid hormone aldosterone controls blood pressure and plays a significant role in hypertension. Primary Aldosteronism (PAL), a condition caused by the excessive production of aldosterone, is the most common, curable form of hypertension. I will identify the molecular mechanisms responsible for PAL, to advance the development of new diagnostic tools and identification of novel therapeutic targets.
Insulin Regulated Aminopeptidase: A New Cardiovascular Target
Funder
National Health and Medical Research Council
Funding Amount
$672,650.00
Summary
Cardiovascular disease, leading to heart attack or stroke is the largest cause of death in Australia. We have evidence that inhibition of a newly described enzyme (IRAP) by angiotensin IV is protective in a model of atherosclerosis. Excitingly we have preliminary data indicating that mice deficient in IRAP have better vascular function therefore we will further investigate this as well as the effectiveness of newly developed IRAP inhibitors in preventing development of cardiovascular disease.